CordenPharma Acquires the Assets of ORPEGEN Peptide Chemicals GmbH
Jan 16, 2015
On January 1, 2015 CordenPharma International acquired the assets of Orpegen Peptide Chemicals GmbH, located in Heidelberg, Germany, retaining both their experienced personnel and peptide capabilities. The newly acquired subsidiary, to be named CordenPharma Heidelberg, will provide innovative, cutting-edge process research and non-GMP development services to support the existing global network of CordenPharma’s peptide facilities including Peptisyntha (Brussels, BE), CordenPharma Switzerland (LIestal, CH) and CordenPharma Colorado (Boulder, CO, USA). The addition of CordenPharma Heidelberg’s process development resources will ultimately increase CordenPharma’s market penetration and further contribute to cost-effective manufacturing processes of peptide Active Pharmaceutical Ingredients (APIs), thereby strengthening CordenPharma’s overall peptide technology platform offerings.
This acquisition is a further step in CordenPharma’s strategy to become the leading global supplier of peptides to support the growing industry demand and increasing number of clinical peptides in the pipeline. Together with its newly invested aseptic fill finish capabilities in CordenPharma Caponago, CordenPharma is now uniquely positioned as a world class partner offering fully-integrated pharmaceutical manufacturing services from research grade to final drug product, including secondary packaging and labeling.